| review article | Q7318358 |
| scholarly article | Q13442814 |
| P2093 | author name string | David Eliezer | |
| David Snead | |||
| P2860 | cites work | A role for alpha-synuclein in the regulation of dopamine biosynthesis | Q24293727 |
| Modulation of the trafficking of the human serotonin transporter by human alpha-synuclein | Q24298523 | ||
| The H50Q mutation enhances α-synuclein aggregation, secretion, and toxicity | Q24299289 | ||
| α-Synuclein interacts with the switch region of Rab8a in a Ser129 phosphorylation-dependent manner | Q24300131 | ||
| Alpha-synuclein acts in the nucleus to inhibit histone acetylation and promote neurotoxicity | Q24301946 | ||
| Gaucher disease glucocerebrosidase and α-synuclein form a bidirectional pathogenic loop in synucleinopathies | Q24307627 | ||
| Alpha-synuclein and polyunsaturated fatty acids promote clathrin-mediated endocytosis and synaptic vesicle recycling | Q24311523 | ||
| Evidence that alpha-synuclein does not inhibit phospholipase D | Q24316900 | ||
| c-Abl phosphorylates α-synuclein and regulates its degradation: implication for α-synuclein clearance and contribution to the pathogenesis of Parkinson's disease | Q24318974 | ||
| Attenuation of the norepinephrine transporter activity and trafficking via interactions with alpha-synuclein | Q24323344 | ||
| Reduced glucocerebrosidase is associated with increased α-synuclein in sporadic Parkinson's disease | Q24324577 | ||
| Structure of membrane-bound alpha-synuclein from site-directed spin labeling and computational refinement | Q24569788 | ||
| Site-specific interaction between α-synuclein and membranes probed by NMR-observed methionine oxidation rates | Q24613887 | ||
| Alpha-synuclein promotes SNARE-complex assembly in vivo and in vitro | Q24629968 | ||
| Nuclear and neuritic distribution of serine-129 phosphorylated alpha-synuclein in transgenic mice | Q46094666 | ||
| Optical reporters for the conformation of alpha-synuclein reveal a specific interaction with mitochondria | Q46237585 | ||
| Aggregated alpha-synuclein activates microglia: a process leading to disease progression in Parkinson's disease | Q46404588 | ||
| Alpha-synuclein multistate folding thermodynamics: implications for protein misfolding and aggregation | Q46459763 | ||
| Phosphorylation, lipid raft interaction and traffic of alpha-synuclein in a yeast model for Parkinson | Q46478232 | ||
| GM1 specifically interacts with alpha-synuclein and inhibits fibrillation | Q46548122 | ||
| Phosphorylation of Ser-129 is the dominant pathological modification of alpha-synuclein in familial and sporadic Lewy body disease | Q46593989 | ||
| Nuclear localization of alpha-synuclein and its interaction with histones | Q46597702 | ||
| A combinatorial code for the interaction of alpha-synuclein with membranes | Q46601588 | ||
| Fatty acid incorporation is decreased in astrocytes cultured from alpha-synuclein gene-ablated mice | Q46610362 | ||
| Comparison of structure and dynamics of micelle-bound human alpha-synuclein and Parkinson disease variants | Q46705919 | ||
| Parkinson's disease alpha-synuclein transgenic mice develop neuronal mitochondrial degeneration and cell death. | Q46884563 | ||
| Binding of alpha-synuclein affects the lipid packing in bilayers of small vesicles | Q46925606 | ||
| Localization of alpha-synuclein to mitochondria within midbrain of mice | Q46988909 | ||
| Rapid Anionic Micelle-mediated α-Synuclein Fibrillization in Vitro | Q47609800 | ||
| Conformation and lipid binding properties of four peptides derived from the membrane-binding domain of CTP:phosphocholine cytidylyltransferase | Q47900873 | ||
| Alpha-synuclein has a high affinity for packing defects in a bilayer membrane: a thermodynamics study | Q47930930 | ||
| Alpha-synuclein implicated in Parkinson's disease is present in extracellular biological fluids, including human plasma | Q48183703 | ||
| Accumulation of phosphorylated alpha-synuclein in dopaminergic neurons of transgenic mice that express human alpha-synuclein | Q48185981 | ||
| Alpha-synuclein gene ablation increases docosahexaenoic acid incorporation and turnover in brain phospholipids. | Q48299443 | ||
| Alpha-synuclein adopts an alpha-helical conformation in the presence of polyunsaturated fatty acids to hinder micelle formation. | Q48334596 | ||
| Binding of alpha-synuclein to brain vesicles is abolished by familial Parkinson's disease mutation. | Q48384247 | ||
| Expression and subcellular location of alpha-synuclein during mouse-embryonic development. | Q48418284 | ||
| Cytosolic proteins regulate alpha-synuclein dissociation from presynaptic membranes. | Q48440013 | ||
| Vesicle permeabilization by protofibrillar alpha-synuclein: implications for the pathogenesis and treatment of Parkinson's disease. | Q48830095 | ||
| Alpha-synuclein binding to rab3a in multiple system atrophy. | Q48912140 | ||
| Characterization of the precursor protein of the non-A beta component of senile plaques (NACP) in the human central nervous system. | Q48958079 | ||
| Subcellular localisation of recombinant alpha- and gamma-synuclein. | Q49080795 | ||
| Parkinson's disease, dementia with Lewy bodies and multiple system atrophy are alpha-synucleinopathies. | Q49135439 | ||
| Red blood cells are the major source of alpha-synuclein in blood. | Q50663283 | ||
| Alpha-synuclein is upregulated in neurones in response to chronic oxidative stress and is associated with neuroprotection. | Q51314524 | ||
| Paramagnetism-based NMR restraints provide maximum allowed probabilities for the different conformations of partially independent protein domains. | Q51904823 | ||
| Interaction of human alpha-Synuclein and Parkinson's disease variants with phospholipids. Structural analysis using site-directed mutagenesis. | Q52165843 | ||
| Membrane binding and self-association of alpha-synucleins. | Q52543652 | ||
| Vesicle permeabilization by protofibrillar alpha-synuclein is sensitive to Parkinson's disease-linked mutations and occurs by a pore-like mechanism. | Q54548113 | ||
| Parkinson's Disease-associated α-Synuclein Is a Calmodulin Substrate | Q57886107 | ||
| Mutant and wild type human alpha-synucleins assemble into elongated filaments with distinct morphologies in vitro | Q64865343 | ||
| alpha-Synuclein membrane interactions and lipid specificity | Q74071513 | ||
| Alpha-synuclein overexpression in PC12 and chromaffin cells impairs catecholamine release by interfering with a late step in exocytosis | Q79362817 | ||
| Helical alpha-synuclein forms highly conductive ion channels | Q79928773 | ||
| Inter-helix distances in lysophospholipid micelle-bound alpha-synuclein from pulsed ESR measurements | Q80040712 | ||
| Antiparallel arrangement of the helices of vesicle-bound alpha-synuclein | Q81361350 | ||
| Detection of oligomeric forms of alpha-synuclein protein in human plasma as a potential biomarker for Parkinson's disease | Q82686303 | ||
| Different sub-cellular localization of alpha-synuclein in the C57BL\6J mouse's central nervous system by two novel monoclonal antibodies | Q82964460 | ||
| Direct evidence of coexisting horseshoe and extended helix conformations of membrane-bound alpha-synuclein | Q83316967 | ||
| Molecular basis for the glycosphingolipid-binding specificity of α-synuclein: key role of tyrosine 39 in membrane insertion | Q83595829 | ||
| Divergent effects of the H50Q and G51D SNCA mutations on the aggregation of α-synuclein | Q88196390 | ||
| Membrane Curvature Induction and Tubulation Are Common Features of Synucleins and Apolipoproteins | Q24633488 | ||
| Inclusion formation and neuronal cell death through neuron-to-neuron transmission of alpha-synuclein | Q24655848 | ||
| Alpha-synuclein blocks ER-Golgi traffic and Rab1 rescues neuron loss in Parkinson's models | Q24683059 | ||
| α-Synuclein assembles into higher-order multimers upon membrane binding to promote SNARE complex formation | Q26269838 | ||
| Systematic mutagenesis of α-synuclein reveals distinct sequence requirements for physiological and pathological activities | Q26269871 | ||
| Native α-synuclein induces clustering of synaptic-vesicle mimics via binding to phospholipids and synaptobrevin-2/VAMP2 | Q26269886 | ||
| Double-knockout mice for alpha- and beta-synucleins: effect on synaptic functions | Q26269963 | ||
| Function and dysfunction of α-synuclein: probing conformational changes and aggregation by single molecule fluorescence | Q27026292 | ||
| NMR Structure of Calmodulin Complexed to an N-Terminally Acetylated α-Synuclein Peptide | Q27677491 | ||
| Structural Basis for Autoinhibition of CTP:Phosphocholine Cytidylyltransferase (CCT), the Regulatory Enzyme in Phosphatidylcholine Synthesis, by Its Membrane-binding Amphipathic Helix | Q27680683 | ||
| Parkinson's disease dementia: convergence of α-synuclein, tau and amyloid-β pathologies | Q27686837 | ||
| Mutation in the alpha-synuclein gene identified in families with Parkinson's disease | Q27860459 | ||
| alpha-Synuclein locus triplication causes Parkinson's disease | Q27860533 | ||
| Synucleins are a novel class of substrates for G protein-coupled receptor kinases | Q28138274 | ||
| alpha-Synuclein shares physical and functional homology with 14-3-3 proteins | Q28139698 | ||
| Constitutive phosphorylation of the Parkinson's disease associated alpha-synuclein | Q28141645 | ||
| alpha-Synuclein interacts with phospholipase D isozymes and inhibits pervanadate-induced phospholipase D activation in human embryonic kidney-293 cells | Q28217032 | ||
| Phospholipase D | Q28253553 | ||
| Mitochondrial dysfunction and oxidative stress in neurodegenerative diseases | Q28269333 | ||
| Molecular anatomy of a trafficking organelle | Q28274481 | ||
| Lewy body-like pathology in long-term embryonic nigral transplants in Parkinson's disease | Q28275257 | ||
| Subcellular localization of wild-type and Parkinson's disease-associated mutant alpha -synuclein in human and transgenic mouse brain | Q28509158 | ||
| Alpha-synuclein gene deletion decreases brain palmitate uptake and alters the palmitate metabolism in the absence of alpha-synuclein palmitate binding | Q28510469 | ||
| Synaptic vesicle depletion correlates with attenuated synaptic responses to prolonged repetitive stimulation in mice lacking alpha-synuclein | Q28511573 | ||
| Brain neutral lipids mass is increased in alpha-synuclein gene-ablated mice | Q28513350 | ||
| Synucleins are developmentally expressed, and alpha-synuclein regulates the size of the presynaptic vesicular pool in primary hippocampal neurons | Q28567029 | ||
| Membrane-bound alpha-synuclein has a high aggregation propensity and the ability to seed the aggregation of the cytosolic form | Q28567172 | ||
| Both acidic and basic amino acids in an amphitropic enzyme, CTP:phosphocholine cytidylyltransferase, dictate its selectivity for anionic membranes | Q28569942 | ||
| Alpha-synuclein sequesters arachidonic acid to modulate SNARE-mediated exocytosis | Q28580852 | ||
| Acyl-CoA synthetase activity links wild-type but not mutant alpha-synuclein to brain arachidonate metabolism | Q28586519 | ||
| Aggregation of α-synuclein in S. cerevisiae is associated with defects in endosomal trafficking and phospholipid biosynthesis | Q35138501 | ||
| N-alpha-acetylation of α-synuclein increases its helical folding propensity, GM1 binding specificity and resistance to aggregation | Q35215613 | ||
| Membrane curvature sensing by amphipathic helices: a single liposome study using α-synuclein and annexin B12 | Q35604940 | ||
| Rab11a and HSP90 regulate recycling of extracellular alpha-synuclein | Q35621972 | ||
| Glucocerebrosidase depletion enhances cell-to-cell transmission of α-synuclein | Q35674483 | ||
| Interaction of α-synuclein with vesicles that mimic mitochondrial membranes | Q35740225 | ||
| Alpha-synuclein: normal function and role in neurodegenerative diseases. | Q35749928 | ||
| Acetylated tau, a novel pathological signature in Alzheimer's disease and other tauopathies | Q35776950 | ||
| The amphipathic helix in the exchangeable apolipoproteins: a review of secondary structure and function | Q36031499 | ||
| Impact of N-terminal acetylation of α-synuclein on its random coil and lipid binding properties | Q36058297 | ||
| Molecular pathophysiology of Parkinson's disease | Q36196507 | ||
| Remodeling of lipid vesicles into cylindrical micelles by α-synuclein in an extended α-helical conformation. | Q36216084 | ||
| Characterization of semisynthetic and naturally Nα-acetylated α-synuclein in vitro and in intact cells: implications for aggregation and cellular properties of α-synuclein | Q36217340 | ||
| The Parkinson's disease protein alpha-synuclein disrupts cellular Rab homeostasis | Q36423369 | ||
| Synuclein: a neuron-specific protein localized to the nucleus and presynaptic nerve terminal | Q36455215 | ||
| Helix periodicity, topology, and dynamics of membrane-associated alpha-synuclein | Q36476930 | ||
| Large α-synuclein oligomers inhibit neuronal SNARE-mediated vesicle docking | Q36673364 | ||
| Amphipathic helices as mediators of the membrane interaction of amphitropic proteins, and as modulators of bilayer physical properties | Q36683725 | ||
| α-Synuclein membrane association is regulated by the Rab3a recycling machinery and presynaptic activity. | Q36685114 | ||
| Mitochondrial import and accumulation of alpha-synuclein impair complex I in human dopaminergic neuronal cultures and Parkinson disease brain | Q36727241 | ||
| Mitochondrial translocation of alpha-synuclein is promoted by intracellular acidification | Q36791338 | ||
| α-Synuclein can inhibit SNARE-mediated vesicle fusion through direct interactions with lipid bilayers | Q36806739 | ||
| Mitochondrial localization of alpha-synuclein protein in alpha-synuclein overexpressing cells | Q36820108 | ||
| NACP, a protein implicated in Alzheimer's disease and learning, is natively unfolded | Q36830682 | ||
| Methionine sulfoxide reductase A protects dopaminergic cells from Parkinson's disease-related insults | Q36841249 | ||
| A novel α-synuclein missense mutation in Parkinson disease | Q36841475 | ||
| Tubulin polymerization-promoting protein (TPPP/p25α) promotes unconventional secretion of α-synuclein through exophagy by impairing autophagosome-lysosome fusion | Q36928990 | ||
| Acetylated tau neuropathology in sporadic and hereditary tauopathies | Q37062833 | ||
| Interplay of alpha-synuclein binding and conformational switching probed by single-molecule fluorescence. | Q37153744 | ||
| Alterations in corticostriatal synaptic plasticity in mice overexpressing human alpha-synuclein | Q37161459 | ||
| Multiple tight phospholipid-binding modes of alpha-synuclein revealed by solution NMR spectroscopy | Q37258811 | ||
| N-terminal acetylation stabilizes N-terminal helicity in lipid- and micelle-bound α-synuclein and increases its affinity for physiological membranes. | Q37563546 | ||
| Splice isoform and pharmacological studies reveal that sterol depletion relocalizes α-synuclein and enhances its toxicity | Q37612718 | ||
| alpha-synuclein is phosphorylated by members of the Src family of protein-tyrosine kinases | Q34511876 | ||
| Alpha-synuclein can function as an antioxidant preventing oxidation of unsaturated lipid in vesicles | Q34541894 | ||
| A maximum entropy approach to the study of residue-specific backbone angle distributions in α-synuclein, an intrinsically disordered protein | Q34571460 | ||
| Extensive nuclear localization of alpha-synuclein in normal rat brain neurons revealed by a novel monoclonal antibody | Q34574672 | ||
| Effects of curvature and composition on α-synuclein binding to lipid vesicles | Q34590790 | ||
| Mechanism of membrane curvature sensing by amphipathic helix containing proteins | Q34594666 | ||
| Quantification of alpha-synuclein binding to lipid vesicles using fluorescence correlation spectroscopy | Q34646732 | ||
| Tissue transglutaminase-induced aggregation of alpha-synuclein: Implications for Lewy body formation in Parkinson's disease and dementia with Lewy bodies | Q34763209 | ||
| Semi-quantitative analysis of alpha-synuclein in subcellular pools of rat brain neurons: an immunogold electron microscopic study using a C-terminal specific monoclonal antibody | Q34837474 | ||
| Impaired dopamine storage resulting from alpha-synuclein mutations may contribute to the pathogenesis of Parkinson's disease | Q34915213 | ||
| Acceleration of oligomerization, not fibrillization, is a shared property of both alpha-synuclein mutations linked to early-onset Parkinson's disease: implications for pathogenesis and therapy | Q34964783 | ||
| Increased expression of alpha-synuclein reduces neurotransmitter release by inhibiting synaptic vesicle reclustering after endocytosis | Q35058315 | ||
| The acetylation of tau inhibits its function and promotes pathological tau aggregation | Q35059866 | ||
| Direct membrane association drives mitochondrial fission by the Parkinson disease-associated protein alpha-synuclein | Q35063363 | ||
| Alpha-synuclein populates both elongated and broken helix states on small unilamellar vesicles | Q35065209 | ||
| α-Synuclein and ALPS motifs are membrane curvature sensors whose contrasting chemistry mediates selective vesicle binding. | Q35102466 | ||
| Defective membrane interactions of familial Parkinson's disease mutant A30P alpha-synuclein | Q43866953 | ||
| The Parkinson's disease-associated H50Q mutation accelerates α-Synuclein aggregation in vitro | Q43977429 | ||
| Methionine oxidation inhibits fibrillation of human alpha-synuclein in vitro | Q44026039 | ||
| The nuclear accumulation of alpha-synuclein is mediated by importin alpha and promotes neurotoxicity by accelerating the cell cycle | Q44134726 | ||
| alpha-Synuclein exhibits competitive interaction between calmodulin and synthetic membranes | Q44163187 | ||
| Phosphorylated alpha-synuclein is ubiquitinated in alpha-synucleinopathy lesions | Q44177978 | ||
| Lipid binding inhibits alpha-synuclein fibril formation | Q44350640 | ||
| A structural and functional role for 11-mer repeats in alpha-synuclein and other exchangeable lipid binding proteins | Q44466072 | ||
| Ubiquitination of alpha-synuclein in Lewy bodies is a pathological event not associated with impairment of proteasome function | Q44552114 | ||
| α-Synuclein Association with Phosphatidylglycerol Probed by Lipid Spin Labels | Q44641205 | ||
| Spin-label EPR on alpha-synuclein reveals differences in the membrane binding affinity of the two antiparallel helices | Q44772162 | ||
| Tissue transglutaminase catalyzes the formation of alpha-synuclein crosslinks in Parkinson's disease | Q44786885 | ||
| Structural determinants of PLD2 inhibition by alpha-synuclein | Q44806821 | ||
| Basal lipid peroxidation in substantia nigra is increased in Parkinson's disease | Q44808814 | ||
| Effects of Parkinson's disease-linked mutations on the structure of lipid-associated alpha-synuclein | Q44850741 | ||
| Abnormal alpha-synuclein interactions with Rab proteins in alpha-synuclein A30P transgenic mice. | Q44852323 | ||
| alpha-Synuclein-synaptosomal membrane interactions: implications for fibrillogenesis | Q44986582 | ||
| Lipid rafts mediate the synaptic localization of alpha-synuclein. | Q44999245 | ||
| Amphipathic helices and membrane curvature | Q37616695 | ||
| Alpha-synuclein, lipids and Parkinson's disease | Q37767943 | ||
| Synuclein modulation of monoamine transporters | Q37852164 | ||
| Protein aggregate spreading in neurodegenerative diseases: problems and perspectives | Q37882078 | ||
| Folding and misfolding of alpha-synuclein on membranes. | Q37938437 | ||
| Pathological roles of α-synuclein in neurological disorders | Q37947720 | ||
| Recent advances in α-synuclein functions, advanced glycation, and toxicity: implications for Parkinson's disease | Q38038126 | ||
| Alpha-synuclein and intracellular trafficking: impact on the spreading of Parkinson's disease pathology. | Q38101508 | ||
| The driving force of alpha-synuclein insertion and amyloid channel formation in the plasma membrane of neural cells: key role of ganglioside- and cholesterol-binding domains | Q38115242 | ||
| Modeling Lewy pathology propagation in Parkinson's disease | Q38164894 | ||
| The association of lipid activators with the amphipathic helical domain of CTP:phosphocholine cytidylyltransferase accelerates catalysis by increasing the affinity of the enzyme for CTP. | Q38290391 | ||
| Enzymatic and cellular characterization of a catalytic fragment of CTP:phosphocholine cytidylyltransferase alpha | Q38325271 | ||
| Lipid regulation of CTP: phosphocholine cytidylyltransferase: electrostatic, hydrophobic, and synergistic interactions of anionic phospholipids and diacylglycerol | Q38354986 | ||
| Effect of Ser-129 phosphorylation on interaction of α-synuclein with synaptic and cellular membranes. | Q38734429 | ||
| Nuclear translocation of alpha-synuclein increases susceptibility of MES23.5 cells to oxidative stress | Q39207279 | ||
| Alpha-synuclein binds large unilamellar vesicles as an extended helix | Q39575705 | ||
| Inhibition of mitochondrial fusion by α-synuclein is rescued by PINK1, Parkin and DJ-1. | Q39655865 | ||
| Determining nuclear localization of alpha-synuclein in mouse brains | Q39788499 | ||
| On the mechanism of internalization of alpha-synuclein into microglia: roles of ganglioside GM1 and lipid raft | Q39849148 | ||
| N-terminal region of alpha-synuclein is essential for the fatty acid-induced oligomerization of the molecules. | Q39930416 | ||
| Mitochondrial association of alpha-synuclein causes oxidative stress | Q40005336 | ||
| Assembly-dependent endocytosis and clearance of extracellular alpha-synuclein. | Q40010392 | ||
| Alpha-synuclein and its disease-causing mutants induce ICAM-1 and IL-6 in human astrocytes and astrocytoma cells | Q40225441 | ||
| Oxidative stress induces nuclear translocation of C-terminus of alpha-synuclein in dopaminergic cells | Q40315913 | ||
| Small ubiquitin-like modifier (SUMO) modification of natively unfolded proteins tau and alpha-synuclein | Q40319470 | ||
| Intravesicular localization and exocytosis of alpha-synuclein and its aggregates. | Q40405368 | ||
| Mutation E46K increases phospholipid binding and assembly into filaments of human alpha-synuclein | Q40501417 | ||
| The formation of highly soluble oligomers of alpha-synuclein is regulated by fatty acids and enhanced in Parkinson's disease | Q40669171 | ||
| Deferoxamine attenuates iron-induced oxidative stress and prevents mitochondrial aggregation and alpha-synuclein translocation in SK-N-SH cells in culture | Q40694082 | ||
| Induction of neuronal cell death by Rab5A-dependent endocytosis of alpha-synuclein | Q40810658 | ||
| Both familial Parkinson's disease mutations accelerate alpha-synuclein aggregation | Q40964871 | ||
| Regulation of phospholipase D2: selective inhibition of mammalian phospholipase D isoenzymes by alpha- and beta-synucleins | Q41043578 | ||
| A 22-mer segment in the structurally pliable regulatory domain of metazoan CTP: phosphocholine cytidylyltransferase facilitates both silencing and activating functions | Q41309849 | ||
| Elucidating the role of C-terminal post-translational modifications using protein semisynthesis strategies: α-synuclein phosphorylation at tyrosine 125. | Q41420722 | ||
| The influence of vesicle size and composition on alpha-synuclein structure and stability | Q42141525 | ||
| N-terminal acetylation of α-synuclein induces increased transient helical propensity and decreased aggregation rates in the intrinsically disordered monomer | Q42247305 | ||
| Alpha-synuclein stimulation of astrocytes: Potential role for neuroinflammation and neuroprotection | Q42412086 | ||
| Altered ion channel formation by the Parkinson's-disease-linked E46K mutant of alpha-synuclein is corrected by GM3 but not by GM1 gangliosides. | Q42647427 | ||
| Allostery in a disordered protein: oxidative modifications to α-synuclein act distally to regulate membrane binding | Q42726460 | ||
| Yeast cells provide insight into alpha-synuclein biology and pathobiology | Q42988614 | ||
| Membrane-bound alpha-synuclein forms an extended helix: long-distance pulsed ESR measurements using vesicles, bicelles, and rodlike micelles | Q43198829 | ||
| Molecular insights into the interaction between alpha-synuclein and docosahexaenoic acid | Q43277862 | ||
| Transplanted dopaminergic neurons develop PD pathologic changes: a second case report | Q43503056 | ||
| Conformational properties of alpha-synuclein in its free and lipid-associated states | Q43564642 | ||
| Broken helix in vesicle and micelle-bound alpha-synuclein: insights from site-directed spin labeling-EPR experiments and MD simulations. | Q43584713 | ||
| The curvature sensitivity of a membrane-binding amphipathic helix can be modulated by the charge on a flanking region | Q43629538 | ||
| Regulation of CTP: phosphocholine cytidylyltransferase activity by the physical properties of lipid membranes: an important role for stored curvature strain energy | Q43720820 | ||
| Exposure to long chain polyunsaturated fatty acids triggers rapid multimerization of synucleins. | Q43735119 | ||
| Protein crosslinking, tissue transglutaminase, alternative splicing and neurodegeneration | Q43819036 | ||
| ??? | Q64767196 | ||
| ??? | Q64770129 | ||
| ??? | Q64781356 | ||
| Alpha-synuclein cooperates with CSPalpha in preventing neurodegeneration | Q28587785 | ||
| Mice lacking alpha-synuclein display functional deficits in the nigrostriatal dopamine system | Q28594502 | ||
| The new mutation, E46K, of alpha-synuclein causes Parkinson and Lewy body dementia | Q29547174 | ||
| Ala30Pro mutation in the gene encoding alpha-synuclein in Parkinson's disease | Q29547175 | ||
| Alpha-synuclein locus duplication as a cause of familial Parkinson's disease | Q29614762 | ||
| Lewy bodies in grafted neurons in subjects with Parkinson's disease suggest host-to-graft disease propagation | Q29615640 | ||
| Stabilization of alpha-synuclein secondary structure upon binding to synthetic membranes | Q29617606 | ||
| Phosphorylation at Ser-129 but not the phosphomimics S129E/D inhibits the fibrillation of alpha-synuclein. | Q30368281 | ||
| Biophysics of α-synuclein membrane interactions. | Q30405705 | ||
| Alpha-synuclein-induced aggregation of cytoplasmic vesicles in Saccharomyces cerevisiae | Q30481396 | ||
| Phosphorylation at S87 is enhanced in synucleinopathies, inhibits alpha-synuclein oligomerization, and influences synuclein-membrane interactions | Q30496792 | ||
| Activated Fyn phosphorylates alpha-synuclein at tyrosine residue 125. | Q31856578 | ||
| Conformation-specific binding of alpha-synuclein to novel protein partners detected by phage display and NMR spectroscopy | Q33300201 | ||
| Differential phospholipid binding of alpha-synuclein variants implicated in Parkinson's disease revealed by solution NMR spectroscopy | Q33627226 | ||
| Synucleins in synaptic plasticity and neurodegenerative disorders | Q33734797 | ||
| The transgenic overexpression of alpha-synuclein and not its related pathology associates with complex I inhibition. | Q33748087 | ||
| Nonaggregated α-synuclein influences SNARE-dependent vesicle docking via membrane binding | Q33824692 | ||
| Synucleins regulate the kinetics of synaptic vesicle endocytosis. | Q33865356 | ||
| Neuron-released oligomeric α-synuclein is an endogenous agonist of TLR2 for paracrine activation of microglia | Q33874305 | ||
| Alpha-synuclein delays endoplasmic reticulum (ER)-to-Golgi transport in mammalian cells by antagonizing ER/Golgi SNAREs | Q33881676 | ||
| alpha-Synuclein occurs in lipid-rich high molecular weight complexes, binds fatty acids, and shows homology to the fatty acid-binding proteins | Q33929879 | ||
| Direct binding and functional coupling of alpha-synuclein to the dopamine transporters accelerate dopamine-induced apoptosis. | Q33941736 | ||
| The novel Parkinson's disease linked mutation G51D attenuates in vitro aggregation and membrane binding of α-synuclein, and enhances its secretion and nuclear localization in cells. | Q33991720 | ||
| The lipid-binding domain of wild type and mutant alpha-synuclein: compactness and interconversion between the broken and extended helix forms | Q34107467 | ||
| A broken alpha -helix in folded alpha -Synuclein | Q34177224 | ||
| Attenuation of dopamine transporter activity by alpha-synuclein | Q34187960 | ||
| The association of alpha-synuclein with membranes affects bilayer structure, stability, and fibril formation | Q34217806 | ||
| Identification of a helical intermediate in trifluoroethanol-induced alpha-synuclein aggregation | Q34279026 | ||
| Characterization of a novel protein regulated during the critical period for song learning in the zebra finch. | Q34303003 | ||
| The precursor protein of non-A beta component of Alzheimer's disease amyloid is a presynaptic protein of the central nervous system | Q34318718 | ||
| Abnormal alpha-synuclein interactions with rab3a and rabphilin in diffuse Lewy body disease. | Q34327884 | ||
| Alpha-synuclein p.H50Q, a novel pathogenic mutation for Parkinson's disease. | Q34330786 | ||
| G51D α-synuclein mutation causes a novel parkinsonian-pyramidal syndrome | Q34335126 | ||
| Structure of membrane-bound alpha-synuclein studied by site-directed spin labeling | Q34375103 | ||
| Structure and dynamics of micelle-bound human alpha-synuclein | Q34379131 | ||
| P275 | copyright license | Creative Commons Attribution-NonCommercial 3.0 Unported | Q18810331 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P433 | issue | 4 | |
| P921 | main subject | Synuclein | Q24767155 |
| P304 | page(s) | 292-313 | |
| P577 | publication date | 2014-12-12 | |
| P1433 | published in | Experimental neurobiology | Q26842060 |
| P1476 | title | Alpha-synuclein function and dysfunction on cellular membranes | |
| P478 | volume | 23 |
| Q89736097 | A Role of Cholesterol in Modulating the Binding of α-Synuclein to Synaptic-Like Vesicles |
| Q42285864 | A pH-dependent switch promotes β-synuclein fibril formation via glutamate residues |
| Q92882497 | AAA+ Protein-Based Technologies to Counter Neurodegenerative Disease |
| Q64065382 | Alpha-Synuclein Continues to Enhance SNARE-Dependent Vesicle Docking at Exorbitant Concentrations |
| Q36131340 | Alpha-Synuclein Proteins Promote Pro-Inflammatory Cascades in Microglia: Stronger Effects of the A53T Mutant |
| Q28079911 | Alpha-Synuclein in Parkinson's Disease: From Pathogenetic Dysfunction to Potential Clinical Application |
| Q26776209 | Alpha-synuclein Toxicity in the Early Secretory Pathway: How It Drives Neurodegeneration in Parkinsons Disease |
| Q47348189 | Alpha-synuclein, proteotoxicity and Parkinson's disease: Search for neuroprotective therapy |
| Q38762606 | An Anatomically Resolved Mouse Brain Proteome Reveals Parkinson Disease-relevant Pathways. |
| Q33790301 | Behavioral Phenotyping and Pathological Indicators of Parkinson's Disease in C. elegans Models |
| Q46332709 | Chromatin-Bound Oxidized α-Synuclein Causes Strand Breaks in Neuronal Genomes in in vitro Models of Parkinson's Disease |
| Q51732038 | Clearing Extracellular Alpha-Synuclein from Cerebrospinal Fluid: A New Therapeutic Strategy in Parkinson's Disease. |
| Q64118819 | Cobra Cardiotoxin Targets Mitochondria to Disrupt Mitochondrial Membrane Structure and Function |
| Q39999661 | Coupling of the non-amyloid-component (NAC) domain and the KTK(E/Q)GV repeats stabilize the α-synuclein fibrils |
| Q54945931 | Different Conformational Subensembles of the Intrinsically Disordered Protein α-Synuclein in Cells. |
| Q40960261 | Direct Observation of the Intrinsic Backbone Torsional Mobility of Disordered Proteins. |
| Q41040224 | Direct Visualization of Model Membrane Remodeling by α-Synuclein Fibrillization |
| Q90477691 | Elucidating Critical Proteinopathic Mechanisms and Potential Drug Targets in Neurodegeneration |
| Q91288432 | Endogenous alpha-synuclein monomers, oligomers and resulting pathology: let's talk about the lipids in the room |
| Q28083809 | Engineering enhanced protein disaggregases for neurodegenerative disease |
| Q64124342 | Femtosecond Hydration Map of Intrinsically Disordered α-Synuclein |
| Q58794919 | Ganglioside lipids accelerate α-synuclein amyloid formation |
| Q36748956 | High expression of α-synuclein in damaged mitochondria with PLA2G6 dysfunction |
| Q54224883 | Impact of membrane curvature on amyloid aggregation. |
| Q38785080 | Implication of Alpha-Synuclein Phosphorylation at S129 in Synucleinopathies: What Have We Learned in the Last Decade? |
| Q48175839 | Insights into the Molecular Mechanisms of Alzheimer's and Parkinson's Diseases with Molecular Simulations: Understanding the Roles of Artificial and Pathological Missense Mutations in Intrinsically Disordered Proteins Related to Pathology |
| Q64263610 | Intrinsically disordered proteins in synaptic vesicle trafficking and release |
| Q36208453 | Leucine-rich repeat kinase 2 (LRRK2) regulates α-synuclein clearance in microglia. |
| Q64795552 | Lipidomic Analysis of α-Synuclein Neurotoxicity Identifies Stearoyl CoA Desaturase as a Target for Parkinson Treatment |
| Q38488082 | Mechanisms of alpha-synuclein action on neurotransmission: cell-autonomous and non-cell autonomous role |
| Q58783524 | Membrane binding, internalization, and sorting of alpha-synuclein in the cell |
| Q28066666 | Membrane remodeling and mechanics: Experiments and simulations of α-Synuclein |
| Q30402710 | Membrane remodeling by amyloidogenic and non-amyloidogenic proteins studied by EPR. |
| Q42321742 | Modulating membrane binding of α-synuclein as a therapeutic strategy |
| Q46303329 | NCEH-1 modulates cholesterol metabolism and protects against α-synuclein toxicity in a C. elegans model of Parkinson's disease |
| Q57025708 | Nanoscopic Characterisation of Individual Endogenous Protein Aggregates in Human Neuronal Cells |
| Q64759312 | Neuropathology and pathogenesis of extrapyramidal movement disorders: a critical update-I. Hypokinetic-rigid movement disorders |
| Q47826150 | Nortriptyline inhibits aggregation and neurotoxicity of alpha-synuclein by enhancing reconfiguration of the monomeric form. |
| Q55341800 | Oleuropein aglycone stabilizes the monomeric α-synuclein and favours the growth of non-toxic aggregates. |
| Q36282886 | Oligomerization and Membrane-binding Properties of Covalent Adducts Formed by the Interaction of α-Synuclein with the Toxic Dopamine Metabolite 3,4-Dihydroxyphenylacetaldehyde (DOPAL). |
| Q58621634 | Potentiating Hsp104 activity via phosphomimetic mutations in the middle domain |
| Q64095970 | Probing Membrane Association of α-Synuclein Domains with VDAC Nanopore Reveals Unexpected Binding Pattern |
| Q91730805 | Probing the Origin of the Toxicity of Oligomeric Aggregates of α-Synuclein with Antibodies |
| Q39205712 | Proteinopathy, oxidative stress and mitochondrial dysfunction: cross talk in Alzheimer's disease and Parkinson's disease |
| Q90108771 | Proteomics-Based Monitoring of Pathway Activity Reveals that Blocking Diacylglycerol Biosynthesis Rescues from Alpha-Synuclein Toxicity |
| Q39010887 | Recent developments in circulating biomarkers in Parkinson's disease: the potential use of miRNAs in a clinical setting. |
| Q91534854 | Regulation of exocytosis and mitochondrial relocalization by Alpha-synuclein in a mammalian cell model |
| Q41728474 | Semisynthetic and in Vitro Phosphorylation of Alpha-Synuclein at Y39 Promotes Functional Partly Helical Membrane-Bound States Resembling Those Induced by PD Mutations |
| Q41911876 | Structural Ensembles of Membrane-bound α-Synuclein Reveal the Molecular Determinants of Synaptic Vesicle Affinity |
| Q37273635 | Structural basis of synaptic vesicle assembly promoted by α-synuclein |
| Q55114623 | Structural characteristics and membrane interactions of tandem α-synuclein oligomers. |
| Q52319335 | Structure and dynamics of the extended-helix state of alpha-synuclein: Intrinsic lability of the linker region. |
| Q39148146 | The Complicated Relationship between Gaucher Disease and Parkinsonism: Insights from a Rare Disease |
| Q92643381 | The N-terminal Acetylation of α-Synuclein Changes the Affinity for Lipid Membranes but not the Structural Properties of the Bound State |
| Q52374337 | The Role of LRRK2 in Neurodegeneration of Parkinson Disease. |
| Q52716959 | The localization of α-synuclein in the process of differentiation of human erythroid cells. |
| Q37181875 | The neural chaperone proSAAS blocks α-synuclein fibrillation and neurotoxicity |
| Q30392912 | Total α-synuclein levels in human blood cells, CSF, and saliva determined by a lipid-ELISA. |
| Q30832756 | Tyrosine Hydroxylase Binding to Phospholipid Membranes Prompts Its Amyloid Aggregation and Compromises Bilayer Integrity. |
| Q93050870 | Untangling the Conformational Polymorphism of Disordered Proteins Associated With Neurodegeneration at the Single-Molecule Level |
| Q26778937 | Αlpha-Synuclein as a Mediator in the Interplay between Aging and Parkinson's Disease |
| Q49240647 | α-Synuclein Aggregated with Tau and β-Amyloid in Human Platelets from Healthy Subjects: Correlation with Physical Exercise. |
| Q64866429 | α-Synuclein and Polyunsaturated Fatty Acids: Molecular Basis of the Interaction and Implication in Neurodegeneration |
| Q49266303 | α-Synuclein may cross-bridge v-SNARE and acidic phospholipids to facilitate SNARE-dependent vesicle docking. |
| Q33615657 | α-Synuclein structural features inhibit harmful polyunsaturated fatty acid oxidation, suggesting roles in neuroprotection |
| Q40986110 | αSynuclein control of mitochondrial homeostasis in human-derived neurons is disrupted by mutations associated with Parkinson's disease. |
Search more.